Patents Represented by Attorney Klauber & Jackson LLC
  • Patent number: 8318756
    Abstract: Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU or 5-FU prodrug is in substantial excess of DPD inhibitor in the patient.
    Type: Grant
    Filed: December 5, 2005
    Date of Patent: November 27, 2012
    Assignee: Adherex Technologies, Inc.
    Inventors: Thomas Spector, William Paul Peters, Donald W. Kufe, Brian Huber
  • Patent number: 8304200
    Abstract: The invention is directed towards a method of enriching a population of cells in those cells that produce an antibody which recognizes an antigen of interest. In particular, an untagged antigen is used in conjunction with a polyclonal antibody to isolate cells recognizing said antigen.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: November 6, 2012
    Assignee: Celltech R&D Limited
    Inventors: Alastair David Griffiths Lawson, Meryn Ruth Griffiths
  • Patent number: 8298773
    Abstract: The invention relates to the diagnosis, monitoring, prognosis, and/or prediction of cancer utilizing the detection or measurement of glycan-protein interactions, particularly glycan-antibody interactions. The invention relates to carbohydrate-containing molecules that are utilized in bioanalytical systems, methods and kits for detecting neoplasia and methods related thereto and based thereon. In an exemplary embodiment glycans or glycopolymers are carried in an array, on beads or in a microfluidic system for diagnostic screening for risk of neoplasia, the existence of neoplasia in a patient, or for treatment monitoring. In such an embodiment, the bioanalytic system identifies binding interactions between molecules in a patient test sample (e.g., glycan compositions) and the glycans or glycopolymers. The glycan-binding compositions may be used to generate an immune response against cancer cell epitopes.
    Type: Grant
    Filed: May 1, 2009
    Date of Patent: October 30, 2012
    Inventors: Marko Vuskovic, Margaret Huflejt
  • Patent number: 8287702
    Abstract: The commercial unipolar activation of water to disinfect raw water supply from rivers or wells, seawater, or waste water from sewage, animal waste, processing plant waste, cooling tower water, swimming pool and spa water, ship ballast water and similar polluted waters. Disinfection is accomplished by hydrogen peroxide and ozone including biocides from chlorine and sulphur compounds in the water that are produced during the electrolytic unipolar activation of the water. Unipolar activation can also be used to perform chemical reactions such as in the activation of seawater. This invention can also produce alkaline water that is beneficial for health.
    Type: Grant
    Filed: September 17, 2008
    Date of Patent: October 16, 2012
    Inventor: Rodolfo Antonio M. Gomez
  • Patent number: 8283459
    Abstract: The present invention relates to methods and compositions for the specific inhibition of kinase suppressor of Ras (KSR). In particular, the invention provides genetic approaches and nucleic acids for the specific inhibition of KSR, particularly of KSR expression. The invention relates to antisense oligonucleotides and the expression of nucleic acid which is substantially complementary to KSR RNA. Oligonucleotide and nucleic acid compositions are provided. The invention provides methods to inhibit KSR, including inhibition of KSR expression. Methods for blocking gf Ras mediated tumorigenesis, metastasis, and for cancer therapy are provided. Methods for conferring radiosensitivity to cells are also provided.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: October 9, 2012
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Richard N. Kolesnick, Hongmei R. Xing
  • Patent number: 8269163
    Abstract: The present invention provides novel radiation associated markers. The radiation associated markers may be one or more of albumin, LTGF-?, or any protein or peptide listed in any one of Tables 1, 2, 3, 4, 5, and 6 provided herein. The present invention also provides methods of assessing exposure to ionizing radiation by determining the presence of one or more radiation associated markers. The methods may optionally include quantifying one or more of the radiation associated markers. The methods may further include comparing the amount of one or more radiation associated markers in the sample determined to be present in the sample with either (i) the amount determined for temporally matched, normal samples or (ii) the amount determined for samples obtained from individuals or subjects that have not been exposed to an elevated level of ionizing radiation. The present invention further provides a method of predicting outcome in a subject after exposure to elevated levels of ionizing radiation.
    Type: Grant
    Filed: May 4, 2009
    Date of Patent: September 18, 2012
    Assignee: New York University
    Inventor: Paul H. Pevsner
  • Patent number: 8263071
    Abstract: The present invention relates to new uses of CDCP1 in the diagnosis, screening, treatment and prophylaxis of ovarian cancer. The invention also provides compositions comprising CDCP1, including vaccines, antibodies that are immunospecific for CDCP1 and agents which interact with or modulate the expression or activity of CDCP1 or which modulate the expression of the nucleic acid which codes for CDCP1.
    Type: Grant
    Filed: October 14, 2009
    Date of Patent: September 11, 2012
    Assignee: UCB Pharma S.A.
    Inventor: Nicola Anne Burgess
  • Patent number: 8258108
    Abstract: The present invention relates to methods and compositions for the specific inhibition of kinase suppressor of Ras (KSR). In particular, the invention provides genetic approaches and nucleic acids for the specific inhibition of KSR, particularly of KSR expression. The invention relates to antisense oligonucleotides and the expression of nucleic acid which is substantially complementary to KSR RNA. Oligonucleotide and nucleic acid compositions are provided. The invention provides methods to inhibit KSR, including inhibition of KSR expression. Methods for blocking gfRas mediated tumorigenesis, metastasis, and for cancer therapy are provided. Methods for conferring radiosensitivity to cells are also provided.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: September 4, 2012
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Richard N. Kolesnick, Hongmei R. Xing
  • Patent number: 8252823
    Abstract: A series of oxazole and thiazole compounds are shown herein to be small molecule inhibitors of the Wnt pathway that specifically target the activity of the stabilized pool of ?-cat oxazole and thiazole compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, cancer, and others.
    Type: Grant
    Filed: January 28, 2009
    Date of Patent: August 28, 2012
    Assignee: New York University
    Inventors: Ramanuj Dasgupta, Foster Gonsalves
  • Patent number: 8242274
    Abstract: A novel [1,2,4]triazolo[1,5-a]pyridine compound is disclosed that has a formula represented by the following: This compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: August 14, 2012
    Assignee: Galapagos NV
    Inventors: Christel Jeanne Marie Menet, Javier Blanc
  • Patent number: 8236367
    Abstract: The method comprises chemical modification of an optionally metallized polymer surface, for example a polycarbonate surface or a polymethacryllate surface functionalized with amino groups, said surfaces being optionally metallized, by treating said polymer surface with a mercaptoalkanoic acid or the salts or derivates thereof. The surfaces obtained by said method may be used as solid supports for immobilizing biomolecules, such as nucleic acids, proteins or membranes.
    Type: Grant
    Filed: December 26, 2008
    Date of Patent: August 7, 2012
    Assignee: Universidad Politecnica de Valencia
    Inventors: María del Carmen Bañuls Polo, Francisco García Piñón, Ángel Maquieira Catalá, Rosa Puchades Pla
  • Patent number: 8227207
    Abstract: The invention relates to the production of ovoproducts containing bioactive peptides from the egg white subjected to enzymatic treatment. Said peptides have an inhibiting activity of the angiotensin converting enzyme (ACE inhibiting activity) in vitro and/or anti-hypertensive activity in rats and/or antioxidant activity. Said ovoproducts, complete hydrolyzates, the fractions thereof with low molecular weight or their constituent peptides could be used as therapeutic substances with ACE inhibiting activity and/or anti-hypertensive activity and/or anti-oxidant activity, either as functional food products, food additives or ingredients or pharmaceutical products for the treatment and/or prevention of hypertension in all its forms in humans or animals and for the treatment and/or prevention of any disorder associated with hypertension in humans or animals.
    Type: Grant
    Filed: January 30, 2006
    Date of Patent: July 24, 2012
    Assignee: Consejo Superior de Investigaciones Cientifcas
    Inventors: Marta Miguel Castro, Rosina Lopez-Alonso Fandiño, Maria Isidra Recio Sanchez, Maria Mercedes Ramos Gonzalez, Amaya Aleixandre De Artiñano
  • Patent number: D665044
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: August 7, 2012
    Assignee: Oy FP Finland Ltd
    Inventor: Mikael Brandt
  • Patent number: D665045
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: August 7, 2012
    Assignee: Oy FP Finland Ltd
    Inventor: Mikael Brandt
  • Patent number: D665046
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: August 7, 2012
    Assignee: Oy FP Finland Ltd
    Inventor: Mikael Brandt
  • Patent number: D665620
    Type: Grant
    Filed: January 12, 2012
    Date of Patent: August 21, 2012
    Assignee: Freshlink Product Development, LLC
    Inventors: Dean B. Chapman, Matthew L. Chin, Olivia Blechschmidt
  • Patent number: D666421
    Type: Grant
    Filed: August 22, 2011
    Date of Patent: September 4, 2012
    Inventor: Elizabeth J. Vivenzio
  • Patent number: D668061
    Type: Grant
    Filed: August 22, 2011
    Date of Patent: October 2, 2012
    Inventor: Elizabeth J. Vivenzio
  • Patent number: D668421
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: October 2, 2012
    Assignee: Vault Finland Oy
    Inventor: Tero Jakku
  • Patent number: D672554
    Type: Grant
    Filed: August 9, 2010
    Date of Patent: December 18, 2012
    Assignee: Iittala Group Oy AB
    Inventor: Anu Penttinen